secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0001193125-23-062072
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos reports Q4 2022 net loss $9.2M, cash $53M; TCR library expanded
-----------------------------------------------------------------------

- Net loss $9.2M in Q4 2022 ($0.04/share) vs $11.8M ($0.05) prior year; full year loss $37.7M.
- Cash and restricted cash $53.0M; expects to fund operations into Q4 2023.
- Expanded TCR library with two new TCRs, doubling potential addressable market; improving patient match rate from 5% to 10%.
- Transitioned to cryopreserved cell product, reducing manufacturing time from 30 to 26 days (13% decrease).
- Phase 2 readiness targeted in 2023; interim data on multiple patients expected mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523062072/0001193125-23-062072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523062072/d457628d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-062072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer